 Ian Carroll
Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cerebrospinal Fluid Leak | 2 | 2024 | 62 | 1.540 |
Why?
| | Atrial Fibrillation | 3 | 2024 | 377 | 0.890 |
Why?
| | Blood Patch, Epidural | 1 | 2024 | 20 | 0.850 |
Why?
| | Patient Reported Outcome Measures | 2 | 2024 | 416 | 0.840 |
Why?
| | Intracranial Hypotension | 1 | 2024 | 56 | 0.790 |
Why?
| | Spine | 1 | 2022 | 179 | 0.680 |
Why?
| | Heart Failure | 4 | 2024 | 2065 | 0.550 |
Why?
| | Bariatric Surgery | 3 | 2025 | 217 | 0.460 |
Why?
| | Electrocardiography | 3 | 2024 | 611 | 0.350 |
Why?
| | Cardiomyopathy, Dilated | 2 | 2025 | 334 | 0.350 |
Why?
| | Eicosapentaenoic Acid | 2 | 2021 | 38 | 0.340 |
Why?
| | Propanolamines | 2 | 2021 | 39 | 0.330 |
Why?
| | Gastric Bypass | 2 | 2023 | 118 | 0.330 |
Why?
| | Gastrointestinal Microbiome | 3 | 2025 | 699 | 0.320 |
Why?
| | Obesity, Morbid | 2 | 2025 | 271 | 0.290 |
Why?
| | Adrenergic beta-Antagonists | 3 | 2025 | 228 | 0.230 |
Why?
| | Butyrates | 1 | 2025 | 60 | 0.220 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2024 | 72 | 0.220 |
Why?
| | Receptors, Adrenergic, beta-1 | 2 | 2021 | 23 | 0.220 |
Why?
| | Multicenter Studies as Topic | 1 | 2024 | 321 | 0.200 |
Why?
| | Ventricular Fibrillation | 1 | 2023 | 60 | 0.200 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2023 | 91 | 0.190 |
Why?
| | Ventricular Remodeling | 1 | 2025 | 257 | 0.190 |
Why?
| | Antifibrinolytic Agents | 1 | 2023 | 50 | 0.190 |
Why?
| | ST Elevation Myocardial Infarction | 1 | 2023 | 55 | 0.190 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2021 | 44 | 0.180 |
Why?
| | Ventricular Function, Left | 1 | 2025 | 502 | 0.180 |
Why?
| | Blood Coagulation Disorders | 1 | 2023 | 176 | 0.180 |
Why?
| | Heart Rate | 1 | 2025 | 802 | 0.170 |
Why?
| | Psychometrics | 1 | 2024 | 730 | 0.170 |
Why?
| | Biological Products | 1 | 2023 | 231 | 0.160 |
Why?
| | Cognition | 2 | 2025 | 1179 | 0.160 |
Why?
| | Case-Control Studies | 2 | 2024 | 3577 | 0.150 |
Why?
| | Middle Aged | 7 | 2025 | 33811 | 0.150 |
Why?
| | Hyperinsulinism | 1 | 2020 | 122 | 0.150 |
Why?
| | Phosphodiesterase 3 Inhibitors | 1 | 2019 | 13 | 0.150 |
Why?
| | Venous Thromboembolism | 1 | 2023 | 324 | 0.150 |
Why?
| | Blood Pressure | 1 | 2025 | 1739 | 0.140 |
Why?
| | Male | 13 | 2025 | 68299 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2024 | 1523 | 0.140 |
Why?
| | Microinjections | 1 | 2018 | 86 | 0.140 |
Why?
| | Humans | 18 | 2025 | 139072 | 0.130 |
Why?
| | Prospective Studies | 3 | 2025 | 7666 | 0.130 |
Why?
| | Organoids | 1 | 2018 | 119 | 0.130 |
Why?
| | Data Interpretation, Statistical | 1 | 2018 | 364 | 0.130 |
Why?
| | Hypertension | 1 | 2025 | 1250 | 0.130 |
Why?
| | Female | 11 | 2025 | 74071 | 0.130 |
Why?
| | Hyperglycemia | 1 | 2020 | 358 | 0.130 |
Why?
| | Colon | 1 | 2018 | 284 | 0.120 |
Why?
| | Gastrointestinal Tract | 1 | 2018 | 203 | 0.120 |
Why?
| | Treatment Outcome | 3 | 2025 | 10930 | 0.120 |
Why?
| | Feeding and Eating Disorders | 1 | 2017 | 168 | 0.110 |
Why?
| | Models, Statistical | 1 | 2018 | 666 | 0.110 |
Why?
| | Cohort Studies | 1 | 2024 | 5749 | 0.100 |
Why?
| | Receptors, Adrenergic | 2 | 2023 | 21 | 0.100 |
Why?
| | Exercise | 1 | 2025 | 2086 | 0.100 |
Why?
| | Aged | 4 | 2025 | 24186 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 1 | 2022 | 3640 | 0.080 |
Why?
| | Stroke Volume | 2 | 2025 | 584 | 0.080 |
Why?
| | Feces | 2 | 2025 | 486 | 0.070 |
Why?
| | Adult | 4 | 2025 | 38428 | 0.070 |
Why?
| | Polymorphism, Genetic | 2 | 2023 | 624 | 0.070 |
Why?
| | Sex Characteristics | 2 | 2023 | 770 | 0.070 |
Why?
| | Proof of Concept Study | 1 | 2025 | 85 | 0.060 |
Why?
| | Enema | 1 | 2025 | 47 | 0.060 |
Why?
| | Genotype | 2 | 2021 | 1849 | 0.060 |
Why?
| | Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2025 | 36 | 0.060 |
Why?
| | Potassium Channels | 1 | 2025 | 149 | 0.050 |
Why?
| | Accelerometry | 1 | 2025 | 109 | 0.050 |
Why?
| | Mice | 4 | 2023 | 17836 | 0.050 |
Why?
| | Cardiovascular Agents | 1 | 2025 | 156 | 0.050 |
Why?
| | Muscle Proteins | 1 | 2025 | 239 | 0.050 |
Why?
| | Thromboplastin | 1 | 2023 | 73 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2025 | 556 | 0.050 |
Why?
| | Norepinephrine | 1 | 2023 | 192 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2020 | 2854 | 0.050 |
Why?
| | Mice, Obese | 1 | 2021 | 67 | 0.050 |
Why?
| | Heparin | 1 | 2023 | 258 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2023 | 310 | 0.040 |
Why?
| | Th17 Cells | 1 | 2021 | 108 | 0.040 |
Why?
| | Receptors, Chemokine | 1 | 2020 | 49 | 0.040 |
Why?
| | Adipose Tissue, White | 1 | 2020 | 43 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2025 | 1057 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 1949 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2021 | 247 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2021 | 368 | 0.040 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2019 | 8 | 0.040 |
Why?
| | Metoprolol | 1 | 2019 | 25 | 0.040 |
Why?
| | Triglycerides | 1 | 2021 | 513 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2021 | 442 | 0.040 |
Why?
| | Pharmacogenomic Variants | 1 | 2019 | 33 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 554 | 0.040 |
Why?
| | Gastrectomy | 1 | 2020 | 132 | 0.040 |
Why?
| | Glucose Intolerance | 1 | 2020 | 146 | 0.040 |
Why?
| | Pharmacogenomic Testing | 1 | 2019 | 60 | 0.040 |
Why?
| | Animals | 4 | 2023 | 37261 | 0.040 |
Why?
| | Bifidobacterium adolescentis | 1 | 2018 | 1 | 0.040 |
Why?
| | Yersinia pseudotuberculosis | 1 | 2018 | 4 | 0.040 |
Why?
| | Hemorrhage | 1 | 2023 | 747 | 0.040 |
Why?
| | Anticoagulants | 1 | 2023 | 667 | 0.040 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2020 | 220 | 0.040 |
Why?
| | Cyclic AMP | 1 | 2019 | 219 | 0.040 |
Why?
| | Mass Spectrometry | 1 | 2021 | 739 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2023 | 2172 | 0.040 |
Why?
| | Signal Transduction | 2 | 2023 | 5095 | 0.030 |
Why?
| | Pharmacogenetics | 1 | 2019 | 164 | 0.030 |
Why?
| | Myocardial Contraction | 1 | 2019 | 303 | 0.030 |
Why?
| | Video Recording | 1 | 2018 | 181 | 0.030 |
Why?
| | Mortality | 1 | 2019 | 360 | 0.030 |
Why?
| | Phenotype | 1 | 2025 | 3145 | 0.030 |
Why?
| | Glucose | 1 | 2021 | 1032 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1281 | 0.030 |
Why?
| | Single-Cell Analysis | 1 | 2018 | 322 | 0.030 |
Why?
| | Precision Medicine | 1 | 2019 | 423 | 0.030 |
Why?
| | Myocytes, Cardiac | 1 | 2019 | 513 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 996 | 0.030 |
Why?
| | Escherichia coli | 1 | 2018 | 827 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2021 | 1994 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2139 | 0.020 |
Why?
| | Inflammation | 1 | 2023 | 2853 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2021 | 5153 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 5532 | 0.020 |
Why?
| | Liver | 1 | 2020 | 1807 | 0.020 |
Why?
| | Time Factors | 1 | 2021 | 6869 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2020 | 5805 | 0.020 |
Why?
| | Obesity | 1 | 2020 | 2995 | 0.020 |
Why?
| | Young Adult | 1 | 2017 | 13378 | 0.010 |
Why?
| | Adolescent | 1 | 2017 | 21594 | 0.010 |
Why?
|
|
Carroll's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|